NASDAQ:ATRC AtriCure (ATRC) Stock Price, News & Analysis $37.37 +2.33 (+6.65%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$37.35 -0.02 (-0.05%) As of 07:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AtriCure Stock (NASDAQ:ATRC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AtriCure alerts:Sign Up Key Stats Today's Range$35.69▼$37.4450-Day Range$25.86▼$37.3752-Week Range$25.36▼$43.18Volume1.19 million shsAverage Volume930,774 shsMarket Capitalization$1.89 billionP/E Ratio177.96Dividend YieldN/APrice Target$49.13Consensus RatingModerate Buy Company Overview AtriCure, Inc. is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF. The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques. In addition, AtriCure markets the LARIAT Suture Delivery Device for left atrial appendage closure to help reduce stroke risk in AF patients who are unable to tolerate long-term anticoagulation therapy. AtriCure continues to invest in R&D initiatives aimed at expanding its surgical and hybrid EP solutions, as well as digital platforms for intraoperative mapping and post-procedural monitoring. AtriCure operates internationally with sales and distribution channels across North America, Europe, Asia and select emerging markets. The company collaborates with leading cardiac centers, physician innovators and academic institutions to conduct clinical studies and training programs that support adoption of its technologies. Under the leadership of President and Chief Executive Officer Jonathan M. Cathcart, AtriCure has pursued strategic partnerships and targeted acquisitions to enhance its electrophysiology portfolio and drive long-term growth. The company remains committed to expanding access to safe, effective AF treatments and advancing the standard of care in cardiac surgery and electrophysiology.AI Generated. May Contain Errors. Read More AtriCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreATRC MarketRank™: AtriCure scored higher than 74% of companies evaluated by MarketBeat, and ranked 171st out of 834 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingAtriCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 1 strong buy rating, 6 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialAtriCure has a consensus price target of $49.13, representing about 31.5% upside from its current price of $37.37.Amount of Analyst CoverageAtriCure has only been the subject of 4 research reports in the past 90 days.Read more about AtriCure's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth215.38% Earnings GrowthEarnings for AtriCure are expected to grow by 215.38% in the coming year, from $0.13 to $0.41 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is 177.96, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.04.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is 177.96, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.01.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 3.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.01% of the float of AtriCure has been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 5.68.Change versus previous monthShort interest in AtriCure has recently increased by 9.33%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.75 News SentimentAtriCure has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for AtriCure this week, compared to 3 articles on an average week.Search Interest3 people have searched for ATRC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $85,950.00 in company stock.Percentage Held by Insiders4.00% of the stock of AtriCure is held by insiders.Percentage Held by Institutions99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AtriCure's insider trading history. Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATRC Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: Otsuka Holdings Co (OtherOTSKF) and Atricure (ATRC)July 25 at 2:56 PM | theglobeandmail.comAtricure (ATRC) Receives a Buy from Stifel NicolausJuly 25 at 2:56 PM | theglobeandmail.comSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One under $5 company's High Altitude Head Start technology could bring that down to $20,000 per launch, or $2 million across 100 missions - a 10X cost advantage. It is already flying with paying customers, but shares may not stay this cheap once Wall Street notices.July 28 at 1:00 AM | Freedom Financial (Ad)AtriCure Inc (ATRC) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Profitability ...July 24, 2026 | finance.yahoo.comAtriCure, Inc. (ATRC) Q2 2026 Earnings Call TranscriptJuly 23, 2026 | seekingalpha.comAtriCure Reports Q2 2026 Results: Full Earnings Call TranscriptJuly 23, 2026 | benzinga.comAtriCure Reports Second Quarter 2026 Financial ResultsJuly 23, 2026 | businesswire.comAtriCure to Announce Second Quarter 2026 Financial ResultsJuly 2, 2026 | businesswire.comSee More Headlines ATRC Stock Analysis - Frequently Asked Questions How have ATRC shares performed this year? AtriCure's stock was trading at $39.56 at the beginning of 2026. Since then, ATRC stock has decreased by 5.5% and is now trading at $37.37. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) issued its quarterly earnings data on Thursday, July, 23rd. The medical device company reported $0.18 EPS for the quarter, topping analysts' consensus estimates of $0.00 by $0.18. The medical device company had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a net margin of 1.85% and a trailing twelve-month return on equity of 2.37%. Read the conference call transcript. Does AtriCure have any subsidiaries? The following companies are subsidiaries of AtriCure: SentreHEART. Who are AtriCure's major shareholders? Top institutional investors of AtriCure include Wasatch Advisors LP (0.46%), Assenagon Asset Management S.A. (0.12%), Handelsbanken Fonder AB (0.05%) and Tactive Advisors LLC (0.03%). Insiders that own company stock include Salvatore Privitera, Vinayak Doraiswamy, Justin J Noznesky, Karl S Dahlquist, Sven Wehrwein, Regina E Groves, Karen Prange and Maggie Yuen. View institutional ownership trends. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD). Company Calendar Last Earnings7/23/2026Today7/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1d) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 ATRC's financial health is in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ATRC CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,300Year Founded2000Price Target and Rating Average Price Target for AtriCure$49.13 High Price Target$55.00 Low Price Target$36.00 Potential Upside/Downside+31.5%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$0.21 Trailing P/E Ratio177.96 Forward P/E Ratio287.46 P/E GrowthN/ANet Income-$11.45 million Net Margins1.85% Pretax Margin-0.59% Return on Equity2.37% Return on Assets1.79% Debt Debt-to-Equity Ratio0.15 Current Ratio4.29 Quick Ratio3.18 Sales & Book Value Annual Sales$534.53 million Price / Sales3.54 Cash Flow$0.33 per share Price / Cash Flow111.95 Book Value$9.89 per share Price / Book3.78Miscellaneous Outstanding Shares50,640,000Free Float48,615,000Market Cap$1.89 billion OptionableOptionable Beta1.24 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ATRC) was last updated on 7/28/2026 by MarketBeat.com Staff. From Our PartnersSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredA 50-year dollar arrangement just ended - what it means for youIn 1974, Henry Kissinger helped create the U.S.-Saudi Arabia Joint Commission on Economic Cooperation - a litt...Golden Portfolio | SponsoredWhat Elon told his top shareholders in TexasLate last year, Elon Musk gathered top shareholders at Tesla's Texas Gigafactory to unveil a plan to double Am...Banyan Hill Publishing | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBofA: Digital Dollar Coming 2025-2030A little-known meeting in 1910 cost the average American family their entire financial freedom. They met in se...Decentralized Masters | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
